The rising incidence of infections acquired in healthcare environments has seen demand for infection related treatments increase. In a new report, "Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products" from CompaniesandMarkets.com, in 2016, the healthcare-acquired infection control market is expected to be worth in excess of $30 billion, having grown from a 2011 figure of $19 billion, at a CAGR of 9.5 percent. In the U.S., it is estimated that healthcare-acquired infections (HAIs) cause the deaths ofÂ more thanÂ 100,000 patients a year.
In recent years, there has been a marked increase in the number of patients developing infections following admittance into hospital and other healthcare settings. HAIs are bacterial, fungal or viral infections which can be contracted in several ways: via surgical procedures, routine care, or from use of medical devices such as catheters and IV lines.
The use of exploratory surgery and interventional procedures is also on the rise, increasing potential opportunities for infection. Furthermore, clinicians are also noting rising resistance to antibiotics used to treat infections, compounding demand for effective and safe HAI treatments and technologies.
The largest HAI market segment is infection control devices and products, worth $8.3 billion in 2010; forecast to achieve $10.3 billion by 2011 and $18.3 billion by 2016. This represents a robust 12 percentÂ CAGR over the reporting period, which is more than double the 5.8 percentÂ CAGR forecast for the HAI pharmaceutical treatments segment which is expecting to see revenues of $6 billion by 2016.
Published in August 2011, the 201-page study examines the HAI market for the period 2010-2016, analyzing devices, therapies and pharmaceuticals by treatment area and treatment type.